The plan’s risks are concentrated in execution, credit and funding rather than in market demand, which is well established. The matrix below sets out the principal risks, their assessed severity and the mitigants; the sensitivity analysis then quantifies the exposure of equity value to the key drivers.
|
Risk |
Severity |
Mitigation |
|---|---|---|
|
Distribution shortfall |
High |
Multi-channel build (digital, field, agent, partners); referral engine; staged targets. |
|
Lending credit losses |
High |
Settlement-linked repayment; AI underwriting; ring-fenced entity; staged limits; ~7% ECL. |
|
Warehouse not secured |
High |
Early DFI/bank engagement; R100m first-loss layer; condition-precedent to lending scale. |
|
Regulatory / licensing delay |
Medium |
Parallel licensing workstream; dedicated CRO; R25m compliance allocation. |
|
Take-rate compression beyond plan |
Medium |
Volume-led model; margin defended by lending & SaaS mix, not pricing. |
|
Currency volatility (regional) |
Medium |
CMA/rand-linked entry first; multi-currency platform; regional diversification. |
|
Key-person / scaling |
Medium |
Board oversight; key-person cover; equity incentives; second-layer management build. |
|
Competitive response |
Medium |
Speed to scale; regional reach; integrated switching costs. |
Sensitivity analysis
Equity value is most sensitive to the exit multiple and to FY2031 revenue — both functions of successful scaling — and materially less sensitive to the operational and funding-cost variables. This concentrates the diligence question on the credibility of the growth build rather than on model mechanics.
NoteWhere to focus diligence
The two largest swing factors — exit multiple and revenue delivery — both reduce to one question: can VeloraPay acquire and retain merchants at the modelled pace across five countries? Every other risk is second-order. Diligence effort should be weighted accordingly: the commercial and distribution plan, the calibre of the team executing it, and the realism of the merchant-acquisition curve.